An efficacy and safety report based on randomized controlled single-blinded multi-centre clinical trial of ZingiVir-H, a novel herbo-mineral formulation designed as an add-on therapy in adult patients with mild to moderate COVID-19.

PLoS One · 2022 · PMC9725144 · PMID 36472969

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp -value<0.0001actually significant

The hazard ratio in the Cox proportional hazards model is 2.619 (95% CI 1.733–3.956) with a highly significant p -value<0.0001, indicated that the ZingiVir-H treated group had a significant recovery period.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.